Hemera
  • Company
    • About us
    • Team
    • Job opportunities
  • Cell therapy
    • REMaST®️
    • Preclinical results
    • Clinical trials
  • Newsroom
    • Highlights
    • News and events
    • Videos
    • Interviews
  • Publications
  • Investors
  • English
    • Italiano (Italian)
Select Page

Hemera Named Finalist at the 2024 Italian Master Startup Award

Sep 6, 2024 | News, Press Releases

We are pleased to announce that Hemera has been selected as one of the 11 finalists for the Italian Master Startup Award (IMSA), the prestigious prize dedicated to scale-ups born from academic research. The award is promoted by the national network of university...

A study has been initiated to observe patients with traumatic and complete spinal cord injury.

Oct 31, 2023 | Press Releases

The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy. At the starting blocks is the prospective observational clinical study on patients with traumatic and complete spinal cord injury in the acute phase. They will be observed...

The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy

Oct 31, 2023 | Press Releases

The prospective observational clinical study is now underway, involving patients with acute, complete traumatic spinal cord injury, who will be monitored over a 12-month period during their neurorehabilitation journey. Authorized by the respective Ethics Committees,...

Hemera Receives Orphan Drug Designation for REMaST® Therapy

Jun 8, 2023 | News, Press Releases

REMaST® Recognized as an Orphan Drug for Acute Spinal Cord Injuries The advanced cell therapy REMaST®, developed by Hemera, has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition...

Hemera achieves an important milestone with the granting of the patent

Apr 21, 2023 | News, Press Releases

The Italian Patent and Trademark Office Officially Recognizes the Patent for REMaST® Therapy The positive evaluation by the Italian Patent and Trademark Office has led to the long-awaited recognition of REMaST® therapy, two years after the patent application was...

Interview with Cristiana Vignoli, protagonist of the month on Il CUBo

Feb 8, 2023 | Press Releases, Press Review, Press Review

Interview with Cristiana Vignoli, protagonist of the month on Il CUBo Cristiana Vignoli, CEO of Hemera is the protagonist of the month for February in the online magazine Cubo.   In the beautiful interview by Luca de Poli published at the beginning of the month...
« Older Entries

Follow us on social:

  • Follow
  • Follow
  • Follow

HÊMERA SRL

Via Giovanni della Casa, 26
37122 Verona – Italy
VAT IT04819260235
REA: VR – 448793
Mail: info@hemerapharma.com
PEC: hemera@pec.it
Web: hemerapharma.com

OPERATIONAL HEADQUARTERS VERONA

Dipartimento di Diagnostica e Sanità pubblica. Palazzina Medicina Legale – Farmacologia – CIRSAL.

Piazzale L. Scuro, 10 – 37134 Verona (VR)

OPERATIONAL HEADQUARTERS MILAN

Dipartimento di Biotecnologie Mediche e Medicina Traslazionale – BIOMETRA. Laboratorio Interdisciplinare di Tecnologie Avanzate (LITA).

Via Fratelli Cervi, 93 – 20054 Segrate (MI)

Privacy Policy | Cookies policy | Modifica preferenze
Copyright Hemera Srl © 2025
FAQ | Contacts